ATE298244T1 - Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen - Google Patents

Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen

Info

Publication number
ATE298244T1
ATE298244T1 AT00947514T AT00947514T ATE298244T1 AT E298244 T1 ATE298244 T1 AT E298244T1 AT 00947514 T AT00947514 T AT 00947514T AT 00947514 T AT00947514 T AT 00947514T AT E298244 T1 ATE298244 T1 AT E298244T1
Authority
AT
Austria
Prior art keywords
vgf
diseases
treatment
selective binding
monoclonal antibodies
Prior art date
Application number
AT00947514T
Other languages
English (en)
Inventor
Hai Yan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE298244T1 publication Critical patent/ATE298244T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00947514T 1999-07-21 2000-07-19 Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen ATE298244T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14474399P 1999-07-21 1999-07-21
PCT/US2000/019640 WO2001007074A1 (en) 1999-07-21 2000-07-19 Vgf selective binding agents and methods of treating vgf-related disorders

Publications (1)

Publication Number Publication Date
ATE298244T1 true ATE298244T1 (de) 2005-07-15

Family

ID=22509932

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00947514T ATE298244T1 (de) 1999-07-21 2000-07-19 Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen

Country Status (11)

Country Link
EP (1) EP1196188B1 (de)
JP (1) JP2003505428A (de)
AT (1) ATE298244T1 (de)
AU (1) AU779614B2 (de)
CA (1) CA2378845A1 (de)
DE (1) DE60020970T2 (de)
DK (1) DK1196188T3 (de)
ES (1) ES2244456T3 (de)
MX (1) MXPA02000678A (de)
PT (1) PT1196188E (de)
WO (1) WO2001007074A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2446886A1 (en) * 2001-04-06 2002-10-17 Biovision Ag Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents
US7749716B2 (en) * 2004-05-18 2010-07-06 Vermilllion, Inc. Methods of detecting a fragment of neurosecretory protein VGF for diagnosing alzheimer's disease
CA2606177A1 (en) * 2005-04-27 2006-11-09 Takeda Pharmaceutical Company Limited Novel polypeptide and use thereof
WO2007013586A1 (ja) * 2005-07-29 2007-02-01 Kyowa Hakko Kogyo Co., Ltd. 新規ペプチド
GB201201332D0 (en) * 2012-01-26 2012-03-14 Imp Innovations Ltd Method

Also Published As

Publication number Publication date
DK1196188T3 (da) 2005-11-07
DE60020970T2 (de) 2006-05-11
DE60020970D1 (de) 2005-07-28
EP1196188A1 (de) 2002-04-17
JP2003505428A (ja) 2003-02-12
WO2001007074A1 (en) 2001-02-01
ES2244456T3 (es) 2005-12-16
MXPA02000678A (es) 2002-07-02
PT1196188E (pt) 2005-10-31
CA2378845A1 (en) 2001-02-01
AU6110300A (en) 2001-02-13
AU779614B2 (en) 2005-02-03
EP1196188B1 (de) 2005-06-22

Similar Documents

Publication Publication Date Title
DE60028970D1 (de) An her2 bindende peptidverbindungen
ATE403680T1 (de) Herstellung tetravalenter antikörper
DK0804236T3 (da) Anvendelse af anti-TNF-antistoffer som lægemidler til behandling af sygdomme, som involverer forhøjede interleukin-6-serumniveauer
NO20061736L (no) Krystallform av epotilon B
ATE337780T1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
AU2002305450A1 (en) Proteomimetic compounds and methods
ATE420097T1 (de) Substituierte sapogenine und ihre verwendung
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
EP1558766A4 (de) Verwendung von a33-antigenen und jam-it
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
ATE235551T1 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
DE60024997D1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE255094T1 (de) Piperazinderivate zur behandlung der niedrigen harnwege
ATE402958T1 (de) Antagonisten des ige-rezeptors
TR200200278T2 (tr) Kalsilitik bileşimler
ATE494903T1 (de) Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden
DE60020970D1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
DE60005526D1 (de) Verwendung von 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine zur behandlung von erkrankungen des magen-darm-traktes
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1196188

Country of ref document: EP

REN Ceased due to non-payment of the annual fee